Factor XIII Deficiency Clinical Trial
Official title:
A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder
associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to
patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting
blood in the usual clotting process, thereby preventing bleeding.
In this study, patients will be treated with FXIII Concentrate (Human) and followed closely
to determine that they receive the dose that will best minimize the chance of bruising and
bleeding.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00945906 -
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
|
Phase 3 | |
| Recruiting |
NCT01106937 -
Factor XIII and Pulmonary Embolism in Neurosurgical Patients
|
N/A | |
| Completed |
NCT03523624 -
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
|
||
| Completed |
NCT00883090 -
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
|
Phase 2 | |
| Not yet recruiting |
NCT03188913 -
Factor XIII in Major Burns Coagulation
|
N/A | |
| Completed |
NCT00735579 -
Wound Healing Abnormalities in Major Abdominal Surgery
|
N/A | |
| Completed |
NCT00640289 -
Clinical Trial of Factor XIII (FXIII) Concentrate
|
N/A |